MEDICO

Medico Remedies Share Price

₹56.89 +3.41 (6.38%)

28 Dec, 2024 02:59

SIP TrendupStart SIP in MEDICO

Start SIP

Performance

  • Low
  • ₹53
  • High
  • ₹59
  • 52 Week Low
  • ₹35
  • 52 Week High
  • ₹92
  • Open Price₹54
  • Previous Close₹53
  • Volume3,517,104

Investment Returns

  • Over 1 Month + 22.98%
  • Over 3 Month + 13.94%
  • Over 6 Month + 32.55%
  • Over 1 Year -33.85%
SIP Lightning

Smart Investing Starts Here Start SIP with Medico Remedies for Steady Growth!

Invest Now

Medico Remedies Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 61.5
  • PEG Ratio
  • -56.6
  • Market Cap Cr
  • 472
  • P/B Ratio
  • 9
  • Average True Range
  • 3.28
  • EPS
  • 0.93
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.15
  • RSI
  • 64.99
  • MFI
  • 62.48

Medico Remedies Financials

Medico Remedies Technicals

EMA & SMA

Current Price
₹56.89
+ 3.41 (6.38%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹50.64
  • 50 Day
  • ₹50.14
  • 100 Day
  • ₹49.32
  • 200 Day
  • ₹51.57

Resistance and Support

56.24 Pivot Speed
  • R3 65.28
  • R2 62.05
  • R1 59.47
  • S1 53.66
  • S2 50.43
  • S3 47.85

What's your outlook on Medico Remedies?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Medico Remedies has an operating revenue of Rs. 141.24 Cr. on a trailing 12-month basis. An annual revenue growth of 2% is not great, Pre-tax margin of 8% is okay, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its key moving averages, around 4% and 4% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 15% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 67 which is a FAIR score but needs to improve its earnings, a RS Rating of 42 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 57 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Medico Remedies Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-12 Quarterly Results
2024-08-12 Quarterly Results
2024-05-09 Audited Results
2024-02-12 Quarterly Results
2023-11-09 Quarterly Results
Date Purpose Remarks
2023-03-16 Split Rs.0.00 split from Rs. 10/- to Rs. 2/-.
Date Purpose Remarks
2021-11-17 Bonus Rs.0.00 issue of equity shares in the ratio of 3:1 of Rs.. 10/-.

Medico Remedies F&O

Medico Remedies Shareholding Pattern

73.34%
0.22%
17.66%
8.78%

About Medico Remedies

  • NSE Symbol
  • MEDICO
  • BSE Symbol
  • 540937
  • Managing Director
  • Mr. Harshit Haresh Mehta
  • ISIN
  • INE630Y01024

Similar Stocks to Medico Remedies

Medico Remedies FAQs

Medico Remedies share price is ₹56 As on 28 December, 2024 | 02:45

The Market Cap of Medico Remedies is ₹472.1 Cr As on 28 December, 2024 | 02:45

The P/E ratio of Medico Remedies is 61.5 As on 28 December, 2024 | 02:45

The PB ratio of Medico Remedies is 9 As on 28 December, 2024 | 02:45

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23